journal article
Jul 01, 2015
Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study
Topics
No keywords indexed for this article. Browse by subject →
References
29
[1]
Ryan "Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study" Lancet Oncol (2015) 10.1016/s1470-2045(14)71205-7
[2]
Beer "Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study" J Clin Oncol (2014)
[3]
Tombal "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study" Lancet Oncol (2014) 10.1016/s1470-2045(14)70129-9
[4]
Horwich "Prostate cancer: ESMO Consensus Conference Guidelines 2012" Ann Oncol (2013) 10.1093/annonc/mds624
[5]
Lycken "Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study" Eur J Cancer (2014) 10.1016/j.ejca.2014.03.279
[6]
Iversen "Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7years" BJU Int (2010) 10.1111/j.1464-410x.2010.09319.x
[7]
Iversen "Bicalutamide (15mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6" J Urol (2004) 10.1097/01.ju.0000139719.99825.54
[8]
Iversen "Bicalutamide 150mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1years" Scand J Urol Nephrol (2006) 10.1080/00365590601017329
[9]
Iversen P, Tammela TLJ, Vaage S, et al. European Urology A Randomised Comparison of Bicalutamide (‘Casodex’) 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer First Report from the Scandinavian Prostatic Cancer Gro. 2002; 42: 204–11.
10.1016/s0302-2838(02)00311-1
[10]
Wirth "Bicalutamide 150mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer program at median followup of 5.4years" J Urol (2004) 10.1097/01.ju.0000140159.94703.80
[11]
Mohler "Prostate cancer, version 2.2014" J Natl Compr Canc Netw (2014) 10.6004/jnccn.2014.0072
[12]
Tyrrell "A randomised comparison of “Casodex” (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer" Eur Urol (1998) 10.1159/000019634
[13]
Iversen "Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3years of followup" J Urol (2000) 10.1016/s0022-5347(05)67032-2
[14]
Kunath "Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer (Review)" Cochrane Libr (2014)
[15]
Wirth "Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer" Eur Urol (2004) 10.1016/j.eururo.2003.10.013
[16]
Dorff "Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study" J Clin Oncol (2011) 10.1200/jco.2010.32.2776
[17]
Immediate versus deferred treatment for advanced prostatic cancer "Initial results of the medical research council trial" Br J Urol (1997)
[18]
Messing "Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy" Lancet Oncol (2006) 10.1016/s1470-2045(06)70700-8
[19]
Schröder "Prostate cancer early versus delayed endocrine treatment of T2–T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European organisation for the research and treatment of cancer protocol 30846 after 13years of FOL" Eur Urol (2009) 10.1016/j.eururo.2008.09.008
[20]
Studer "Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12years of follow-up" Eur Urol (2013)
[21]
Bria "Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials" Cancer (2009) 10.1002/cncr.24392
[22]
Shelley "Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials" Cancer Treat Rev (2009) 10.1016/j.ctrv.2009.05.001
[23]
Sternberg "Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme" BJU Int (2006) 10.1111/j.1464-410x.2006.06088.x
[24]
Abrahamsson "Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer" Eur Urol (2005) 10.1016/j.eururo.2005.09.005
[25]
Iversen "The third analysis of the Early Prostate Cancer programme" BJU Int (2006) 10.1111/j.1464-410x.2006.06118.x
[26]
Dockery "Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer" J Androl (2009) 10.2164/jandrol.108.006924
[27]
Martín-Merino "Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer" Am J Cardiol (2011)
[28]
McLeod "Bicalutamide 150 mg plus standard care vs standard care alone for Early Prostate Cancer" BJU Int (2006) 10.1111/j.1464-410x.2005.06051.x
[29]
Brasso "Differences in survival from prostate cancer in Denmark, Iceland and Sweden" Eur J Cancer (2013) 10.1016/j.ejca.2013.01.008
Metrics
19
Citations
29
References
Details
- Published
- Jul 01, 2015
- Vol/Issue
- 51(10)
- Pages
- 1283-1292
- License
- View
Authors
Cite This Article
Frederik B. Thomsen, Klaus Brasso, Ib J. Christensen, et al. (2015). Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. European Journal of Cancer, 51(10), 1283-1292. https://doi.org/10.1016/j.ejca.2015.03.021
Related
You May Also Like
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E.A. Eisenhauer, P. Therasse · 2009
24,176 citations
Radiomics: Extracting more information from medical images using advanced feature analysis
Philippe Lambin, Emmanuel Rios-Velazquez · 2012
4,981 citations
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress
R.K. Portenoy, H.T. Thaler · 1994
1,262 citations
Etoposide: four decades of development of a topoisomerase II inhibitor
K.R Hande · 1998
784 citations
Quality of life research within the EORTC—the EORTC QLQ-C30
P Fayers, A Bottomley · 2002
731 citations